Clinical Hematology and Blood Transfusion

Clinical Hematology and Blood Transfusion

Clinical Hematology and Blood Transfusion (CHBT) is an open access, peer-reviewed journal with broad scope covering all zones of haematology research, especially novel concepts, new methods, new regimens, new therapeutic agents, and alternative approaches for early detection and intervention of haematology. CHBT publishes interesting and informative reviews on any topic connected with blood, and considers any original research contribution that advocates change in, or illuminates, haematological disorders.

The Journal is supported by an international editorial board consisting of a distinguished team of haematology researchers. CHBT aims at rapid publication of high quality results in haematology research while maintaining rigorous peer-review process.

All the types of articles like Research paper, Case Report, Short research communication, Review, Hypothesis, Method and protocol, new instruments and regimens, Letter to the editor are accepted. With a large international editorial board of experts who are leaders in their fields, CHBT aims at delivering the best communication on the fast moving, and continually evolving, global haematology landscape.

Papers on more general aspects of interest to the blood including haemoglobin, blood cells and platelets are also published. Papers are accepted on a worldwide basis. CHBT welcomes direct submissions of manuscripts from authors.

You are welcome to submit your work to

Open Access Policy: This journal is an open access journal which provides immediate, worldwide, boundary free access to the full content of every distributed article without charging readers or their institutions for access. Readers are given authorization to read, circulate, copy, print, download, search, or link to the full texts of all articles in CHBT.

Editorial Board

Currently we are forming the editorial board

Published Articles

Submit Manuscript

Please submit your manuscript to


JCRM journal has received impact factor of 1.02 for its 2018 volume.